Cefozopran hydrochloride

click on thumbnail to zoom

Cefozopran hydrochloride

SKU: C099

Size

Quantity:

Click 'Bulk Order' for 10 or more

Price:

make selection(s)

Description

Cefozopran HCl is a fourth generation cephalosporin antibiotic and is freely soluble in DMSO and slightly soluble in water.

CAS Number

113981-44-5

Molecular Formula

C₁₉H₁₇N₉O₅S₂•HCl

Molecular Weight

551.99

Mechanism of Action

Similar to β-lactams, cephalosporins interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBP’s are enzymes which catalyze a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Resistance to cephalosporins is commonly due to cells containing plasmid encoded β-lactamases.

Storage Conditions

-20°C

Tariff Code

2941.90.3000

Spectrum

Cefozopran is a broad spectrum antibiotic targeting a wide range of gram positive and gram negative bacteria including Pseudomonas aeruginosa.

Applications

Microbiology Applications

Cefozopran has been shown to be useful against the multi drug resistant MRSA when used in combination with other antibiotics including vancomycin and teicoplanin.

Specifications

Form

Powder

Technical Data

References

Hayashi, R., and A. Lmada. "Therapeutic Effect of Cefozopran (SCE-2787), a New Parenteral Cephalosporin, against Experimental Infections in Mice." Antimicrobial Agents and Chemotherapy 37.1 (1993): 100-05. www.ncbi.gov. Web. 27 Aug. 2012.

Georgopapadakou, N. H. "Mechanisms of Action of Cephalosporin 3'-quinolone Esters, Carbamates, and Tertiary Amines in Escherichia Coli." American Society for Microbiology 37.3 (1992): 559-65. Antimicrobial Agents and Chemotherapy. Web. 21 Aug. 2012.

Toyokawa, M., and Et Al. "In Vitro Combined Effects of Cefozopran/teicoplanin and Cefozopran/vancomycin on Methicillin-resistant Staphylococcus Aureus." Journal of Chemotherapy 15.1 (2003): 31-36. Ncbi.gov. Web. 18 Sept. 2012.